Psychology & Psychiatry

Schizophrenia: Researchers observe disease processes in nerve cells

Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining ...

Psychology & Psychiatry

Common brain network links atrophy patterns seen in schizophrenia

A new study led by investigators from Mass General Brigham has identified a unique brain network that links varied patterns of brain atrophy, or shrinkage, associated with schizophrenia. By combining neuroimaging data from ...

Genetics

Genetic risk for schizophrenia linked to a malformed skull

The chromosomal disorder 22q11.2 deletion syndrome (22q) has emerged as one of the strongest risks for schizophrenia. Scientists at St. Jude Children's Research Hospital identified malformed regions of the cerebellum in laboratory ...

Medications

FDA approves Cobenfy for adults with schizophrenia

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

page 6 from 40